GLP-1 receptor agonist therapy provides a net clinical benefit to healthy normal-weight adults aged 55-75.
- Current status
- Insufficient evidenceEvidence stable · Core question
- Why
- No randomized trial has enrolled healthy normal-weight older adults with clinical outcomes. All outcome trials required obesity/overweight, type 2 diabetes, or a specific disease (heart failure, CKD, MASH, Parkinson's, Alzheimer's). Modelling (JACC 2026) projects attenuated benefit in non-obese groups and is not evidence. Harms (gastrointestinal, gallbladder, lean-mass loss, NAION signal) are documented in the treated populations and would apply, possibly more acutely, to people without excess adiposity to lose.
- What would change it
- An adequately powered randomized trial enrolling normal-weight (BMI < 25) participants aged 55 or older.
Clinically meaningful outcomes (events, function, validated cognitive measures), not biomarkers alone.
A prespecified analysis showing benefit independent of weight change.
Follow-up of at least 2-3 years with full reporting of lean mass, bone, nutritional and gastrointestinal harms.
Independent (non-manufacturer) replication or an independent data-analysis group. - Linked studies
- 5 · 1 no direct human evidence · 4 doesn't directly test the claim
- Last updated
- Sep 13, 2026
The status is the collection's own judgment on its assessment scale, not a GRADE certainty rating and not medical advice.
The evidence, sorted by what it shows
No direct human evidence (1)
- Semaglutide and Cardiovascular Outcomes in Obesity without DiabetesRandomized trial · 2023 · Study tier 1 · Different population · Benefit · Industry funded
SELECT required BMI >= 27 and established CVD; mean BMI 33.4. Does not include normal-weight adults.
Doesn't directly test the claim (4)
- Cardiovascular Outcomes of GLP-1-Based Medicines Among People With Overweight and Obesity: An Umbrella Review of Meta-Analyses of Randomized Controlled TrialsUmbrella review · 2026 · Study tier 2 · Different population · Mixed
Umbrella review in people with overweight or obesity: GLP-1 RAs reduced MACE and MI with high-certainty evidence, but these reductions were no longer significant among patients without baseline CVD, and higher arrhythmia risk was found with GLP-1 RAs. Normal-weight adults were not studied.
- Effects of Semaglutide on Body Composition and GFR: A Prespecified Analysis of the SMART TrialRandomized trial · 2026 · Study tier 3 · Different population · Mixed · Industry funded
In 101 adults with CKD and overweight or obesity without type 2 diabetes, 24 weeks of semaglutide changed body weight by -9.1 kg versus placebo; lean body mass changed by -2.5 kg (95% CI -6.6 to 1.6) and fat mass by -3.9 kg (95% CI -7.8 to 0.0), so neither difference excluded zero. It includes no healthy normal-weight adults.
- Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trialRandomized trial · 2025 · Study tier 2 · Different population · Benefit · Industry funded
Prespecified SELECT analysis in people with CVD and BMI 27 or more: MACE benefit was consistent across baseline weight and waist categories, with no linear trend between week-20 weight loss and later MACE, though about 33 percent of benefit was mediated by waist circumference reduction. It cannot be extrapolated to normal-weight adults.
- Mapping the effectiveness and risks of GLP-1 receptor agonistsRetrospective cohort · 2025 · Study tier 3 · Different population · Mixed
Observational cohort of US veterans with diabetes: compared with usual care, GLP-1 RA use was associated with lower risk of substance use and psychotic disorders, seizures, neurocognitive disorders, cardiometabolic disorders and infections, and higher risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, nephrolithiasis, interstitial nephritis and drug-induced pancreatitis. It includes no healthy or normal-weight adults.
How this assessment has changed
- Insufficient evidenceSep 13, 2026 · Evidence stable
initial curated status